Company / Operating Income
Edwards Lifesciences Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$1.3B
FY2025
5-year range
$1.3B / $1.7B
FY2021-FY2025
Trend
-8.3%
vs FY2024
Sector context
#28 of 156
Health Care
What the data says
Edwards Lifesciences's operating income of $1.3B is higher than 82% of companies in the Health Care sector (FY2025). Operating Income has fluctuated over the past 10 years, ranging from $748M in FY2018 to $1.7B in FY2023.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +7.1%. Top quartile in the Health Care sector.
Declined from $1.7B to $1.3B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -5.5%
- 5-Year CAGR
- +7.1%
- 10-Year CAGR
- -
Sector benchmark
+72.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.1%, indicating consistent growth.
- In FY2025, operating income decreased 8.3% year-over-year.
- Ranks #28 out of 156 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | -8.3% |
| FY2024 | $1.4B | -18.4% |
| FY2023 | $1.7B | +12.8% |
| FY2022 | $1.5B | -11.4% |
| FY2021 | $1.7B | +88.3% |
| FY2020 | $897.6M | -21.7% |
| FY2019 | $1.1B | +53.3% |
| FY2018 | $748.2M | -31.3% |
| FY2017 | $1.1B | +45.0% |
| FY2016 | $751.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026